KR101880245B1 - Food Composition for Anti-stress effect - Google Patents
Food Composition for Anti-stress effect Download PDFInfo
- Publication number
- KR101880245B1 KR101880245B1 KR1020160105624A KR20160105624A KR101880245B1 KR 101880245 B1 KR101880245 B1 KR 101880245B1 KR 1020160105624 A KR1020160105624 A KR 1020160105624A KR 20160105624 A KR20160105624 A KR 20160105624A KR 101880245 B1 KR101880245 B1 KR 101880245B1
- Authority
- KR
- South Korea
- Prior art keywords
- stress
- extract
- burdock
- food composition
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 235000013305 food Nutrition 0.000 title claims abstract description 44
- 230000000694 effects Effects 0.000 title abstract description 19
- 230000002180 anti-stress Effects 0.000 title 1
- 240000005528 Arctium lappa Species 0.000 claims abstract description 50
- 235000010518 Canavalia gladiata Nutrition 0.000 claims abstract description 5
- 240000003049 Canavalia gladiata Species 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 63
- 235000003130 Arctium lappa Nutrition 0.000 claims description 49
- 235000008078 Arctium minus Nutrition 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 235000013527 bean curd Nutrition 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000469 ethanolic extract Substances 0.000 claims 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 34
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract description 32
- 229960000890 hydrocortisone Drugs 0.000 abstract description 16
- 229940076279 serotonin Drugs 0.000 abstract description 15
- 230000028327 secretion Effects 0.000 abstract description 12
- 230000036541 health Effects 0.000 abstract description 8
- 229940088597 hormone Drugs 0.000 abstract description 7
- 239000005556 hormone Substances 0.000 abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 7
- 235000013376 functional food Nutrition 0.000 abstract description 6
- 239000002438 stress hormone Substances 0.000 abstract description 3
- 244000068988 Glycine max Species 0.000 description 18
- 235000010469 Glycine max Nutrition 0.000 description 18
- 239000000843 powder Substances 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 235000019634 flavors Nutrition 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000000605 extraction Methods 0.000 description 9
- 229940099472 immunoglobulin a Drugs 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 6
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229960002748 norepinephrine Drugs 0.000 description 6
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 6
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 4
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 4
- 102000013142 Amylases Human genes 0.000 description 4
- 108010065511 Amylases Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102400000739 Corticotropin Human genes 0.000 description 4
- 101800000414 Corticotropin Proteins 0.000 description 4
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 4
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 4
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 235000019418 amylase Nutrition 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 4
- 229960000258 corticotropin Drugs 0.000 description 4
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 4
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229940053128 nerve growth factor Drugs 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000002889 sympathetic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- JYGXADMDTFJGBT-MKIDGPAKSA-N 11alpha-Hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-MKIDGPAKSA-N 0.000 description 3
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 240000001417 Vigna umbellata Species 0.000 description 3
- 235000011453 Vigna umbellata Nutrition 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000004404 adrenal cortex Anatomy 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000002161 passivation Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 244000066764 Ailanthus triphysa Species 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical group COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000004874 Synaptophysin Human genes 0.000 description 2
- 108090001076 Synaptophysin Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000007958 sleep Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 description 1
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 101710115642 Canavalin Proteins 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 244000086363 Pterocarpus indicus Species 0.000 description 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000002934 adrenergic neuron Anatomy 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- -1 and contains arctin Chemical compound 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000010482 emotional regulation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000019990 fruit wine Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- MAYUCBCSAVDUKG-UHFFFAOYSA-N orthoacetic acid Chemical compound CC(O)(O)O MAYUCBCSAVDUKG-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 210000004258 portal system Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- YXJHJCDOUFKMBG-BMZHGHOISA-M riboflavin sodium Chemical compound [Na+].OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)[N-]C2=O YXJHJCDOUFKMBG-BMZHGHOISA-M 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 235000019997 soju Nutrition 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/31—Foods, ingredients or supplements having a functional effect on health having an effect on comfort perception and well-being
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
본 발명은 스트레스 완화용 식품 조성물에 관한 것으로, 구체적으로 작두콩(Canavalia gladiata, 도두(刀豆)), 우엉(Arctium lappa L.), 또는 이들의 혼합물을 포함하여 스트레스 호르몬인 코르티솔(Cortisol)의 분비를 낮추고 행복 호르몬인 세로토닌(Serotonin)의 분비를 증가시키며, 부작용이 없고 인체에 안전한 스트레스 완화용 식품 조성물에 관한 것으로, 건강기능식품 또는 약학 조성물에 포함되어 사용될 수 있다.[0001] The present invention relates to a food composition for stress relief, and more particularly to a composition for suppressing the secretion of Cortisol, which is a stress hormone, including Canavalia gladiata , Arumium lappa L. , And to increase secretion of serotonin, which is a happy hormone. The present invention relates to a food composition for relieving stress which is free from side effects and is safe for the human body, and can be included in a health functional food or a pharmaceutical composition.
Description
본 발명은 스트레스 완화용 식품 조성물에 관한 것으로, 구체적으로 작두콩(Canavalia gladiata, 도두(刀豆))과 우엉(Arctium lappa L.)의 혼합물을 포함하여 스트레스 호르몬인 코르티솔(Cortisol)의 분비를 낮추고 행복 호르몬인 세로토닌(Serotonin)의 분비를 증가시키며, 부작용이 없고 인체에 안전한 스트레스 완화용 식품 조성물에 관한 것이다.The present invention relates to a food composition for stress relief, and more particularly to a food composition for stress relief comprising a mixture of Canavalia gladiata and Arctium lappa L. to lower the secretion of the stress hormone Cortisol, The present invention relates to a food composition which increases the secretion of the hormone serotonin and which is free from side effects and is safe for the human body.
스트레스의 어원은 'Strictus : 팽팽한 혹은 좁은' 또는 'Stringere : 팽팽하다 이며 심리학에서 스트레스 (Stress) 는 스트레스 요인에 대항하기 위한 심신의 변화과정을 뜻하고 우리말로는 정신압박 이라고도 한다.The origin of stress is 'Strictus: tight or narrow' or 'Stringere: tight', and in psychology Stress means the process of change of mind and body to cope with the stressors, which is also called mental pressure.
스트레스는 일상에 만연되어 있는 요소로 유발되며, 거의 모든 질환과 의학적 질병의 발생에 기여한다. Stress is caused by the elements that are prevalent in everyday life and contributes to the occurrence of almost all diseases and medical diseases.
지금까지 스트레스를 치유하기 위하여 진정제, 수면제 투여, 호르몬 요법 등 많은 약물 요법이 연구되고 있으나, 이러한 약물요법은 장기간 사용시 약물에 대한 내성 및 부작용 위험이 있어 지속적 이용이 불가능하므로, 부작용이 없고, 지속적으로 복용할 수 있는 간단하고 효과적인 방법이 요구된다. So far, many drug therapies such as sedatives, hypnotics, and hormone therapy have been studied to relieve stress. However, these pharmacologic therapies do not have side effects because they are resistant to drugs and risks of side effects during long-term use, A simple and effective way to take it is required.
본 발명자들은 장기 복용해도 부작용이 없도록, 천연 식품을 스크리닝하던 중 우수한 스트레스 완화 효능을 갖는 식품 소재로서 작두콩과 우엉을 선별하였으며, 이의 효과를 규명하여 본 발명을 완성하였다.The inventors of the present invention selected soybean curd and burdock as food materials having excellent stress relieving effect during screening of natural foods so as to avoid side effects even after long-term administration, and their effects were studied to complete the present invention.
본 결과물은 농림축산식품부의 재원으로 농림수산식품기술기획평가원의 고부가가치식품기술개발사업의 지원을 받아 연구되었음 (115036-3).This product was funded by the Ministry of Food, Agriculture, Forestry, and Livestock and was supported by the Ministry of Agriculture, Forestry and Fisheries Technology Planning and Evaluation and supported by the High Value Added Food Technology Development Project (115036-3).
관련 선행문헌: 등록특허 제0905386호 Related Prior Art: Registration No. 0905386
등록특허 제1074914호 Patent No. 1074914
등록특허 제1298568호 Patent No. 1298568
본 발명의 목적은 천연 식품 소재를 사용함으로서 부작용이 없어, 장기 복용시에도 인체에 해가 없으며, 또한 발병 전에도 수시로 복용할 수 있어, 예방 및 치유 효과를 나타내는 스트레스 완화용 식품 조성물을 제공하는 것이다. It is an object of the present invention to provide a food composition for stress relief which is free from side effects by using natural food materials and has no harm to human body even when taken for a long period of time and which can be taken at any time before onset,
상기 목적을 달성하기 위하여, 본 발명은 작두콩, 우엉 또는 이들의 혼합물을 포함하는 스트레스 완화용 식품 조성물을 제공한다. 또한, 본 발명의 구체예에서, 상기 작두콩 대신에 이의 싹을 포함할 수 있다.In order to achieve the above object, the present invention provides a food composition for stress relief comprising soybean curd, burdock or a mixture thereof. In addition, in embodiments of the present invention, it may include its bud instead of the soybean curd.
본 발명에 따른 조성물은 작두콩 우엉을을 분말 또는 추출물 형태로 포함할 수 있으며, 이들 혼합 추출물을 분말 또는 건조 및 분쇄되어 분말 형태 또는 농축되어 진액 형태로 직접 포함할 수 있다. The composition according to the present invention may include soybean curd bean as a powder or extract, and these mixed extracts may be directly contained in the form of powders or dried and pulverized powders or concentrated and in the form of liquids.
본 발명의 일 실시예에 의하면, 상기 혼합 추출물은은 작두콩, 우엉 또는 이들의 혼합물을 유기용매추출물, 수추출물, 초임계추출물, 중탕추출물의 형태로 포함할 수 있다.According to one embodiment of the present invention, the mixed extract may include silver algae, burdock or a mixture thereof in the form of an organic solvent extract, a water extract, a supercritical extract, and a hot water extract.
상기 작두콩, 우엉, 또는 이들의 혼합 추출물을 제조하기 위하여 사용되는 추출 용매의 예로는 정제수; 메탄올, 에탄올, 이소프로필알코올, 부탄올 등의 탄소수 1 내지 10의 저급 알코올; 글리세롤, 에틸렌글리콜, 프로필렌 글리콜, 1,3-부틸렌 글리콜 등의 탄소수 2 내지 30의 다가 알코올; 및 석유에테르, 메틸아세테이트, 에틸아세테이트, 벤젠, 헥산, 메틸렌클로라이드, 디에틸에테르, 디클로로메탄, 클로로포름의 등의 탄소수 1 내지 30의 탄화수소계 용매 등을 예로 들 수 있다.Examples of the extraction solvent used for preparing the soybean curd, burdock, or mixed extract thereof include purified water; Lower alcohols having 1 to 10 carbon atoms such as methanol, ethanol, isopropyl alcohol and butanol; Polyhydric alcohols having 2 to 30 carbon atoms such as glycerol, ethylene glycol, propylene glycol, and 1,3-butylene glycol; And hydrocarbon solvents having 1 to 30 carbon atoms such as petroleum ether, methyl acetate, ethyl acetate, benzene, hexane, methylene chloride, diethyl ether, dichloromethane and chloroform.
본 발명의 일 실시예에 의하면, 상기 추출 용매는 물에 대해 에탄올의 부피%로서 50~80%의 용매로 추출한 추출물이 바람직하다. According to an embodiment of the present invention, the extraction solvent is preferably an extract obtained by extracting 50 to 80% by volume of ethanol with respect to water.
상기 작두콩과 우엉의 혼합물은 작두콩과 우엉이 중량비로서 1:3~1:5의 비율로 혼합된 혼합물이 바람직하다The mixture of soybean and burdock is preferably a mixture of soybean and burdock at a weight ratio of 1: 3 to 1: 5
상기 작두콩과 우엉의 혼합 추출물은 각각을 추출 후 혼합하거나, 또는 작두콩과 우엉 원물을 혼합 후 상기 방법으로 동시에 추출하는 것도 가능하다.The mixed extracts of soybean and burdock can be extracted and mixed together, or the soybean and burdock raw materials can be mixed and extracted simultaneously by the above method.
본 발명의 일 실시예에 의하면, 상기 스트레스 완화용 식품 조성물은 스트레스 완화 효과를 나타내는 예방 및/또는 치료를 위한 건강기능식품 조성물로 사용될 수 있다.According to one embodiment of the present invention, the food composition for stress relief can be used as a health functional food composition for prevention and / or treatment showing a stress relieving effect.
본 발명에 따른 스트레스 완화용 식품 조성물은 식품 전체 중량에 대하여 0.0001~90중량%으로 포함될 수 있다.The food composition for stress relief according to the present invention may be contained in an amount of 0.0001 to 90% by weight based on the total weight of the food.
본 발명의 일 실시예에 의하면, 상기 스트레스완화용 식품 조성물은 스트레스 완화 효과를 나타내는 예방 및/또는 치료를 위한 약학 조성물로 사용될 수 있다.According to one embodiment of the present invention, the food composition for stress relief can be used as a pharmaceutical composition for prevention and / or treatment showing a stress-relieving effect.
본 발명의 일 실시예에 의하면, 상기 약학 조성물은 상기 스트레스 완화용 조성물을 1~100mg/체중 kg을 1일 기준 유효량으로 포함할 수 있다.According to one embodiment of the present invention, the pharmaceutical composition may contain the stress-relieving composition in an effective amount of 1 to 100 mg / kg body weight per day.
본 발명의 조성물은 작두콩, 우엉, 또는 이들의 혼합물과 같은 천연 재료를 포함하여, 부작용이 없으며, 특히 장기 복용시에도 부작용이 없어, 식품 조성물에 사용이 가능하다. 또한, 스트레스 호르몬인 코르티솔(Cortisol)의 분비를 낮추고 행복 호르몬인 세로토닌(Serotonin)의 분비를 증가시켜 스트레스 완화 효과가 우수하다. 특히, 스트레스가 많은 직장인, 수험생, 주부 등 스트레스를 받는 현대인들의 스트레스 완화를 위하여 본 발명의 조성물을 사용할 수 있다. The composition of the present invention is free from side effects, including natural materials such as soybean curd, burdock, or a mixture thereof, and can be used in a food composition without adverse effects even when taken on a long-term basis. In addition, the stress hormone Cortisol (Cortisol) secretion and lower the secretion of the hormone Serotonin (Serotonin) to increase the stress relieving effect is excellent. In particular, the composition of the present invention can be used for stress relief of modern people who are stressed, such as office workers, examinees, and housewives.
도 1은 부동화 스트레스유발 생쥐에서 작두콩과 우엉 복합물 섭취에 의한 혈중 IgA 수준 변화 시험 결과이다.
도 2은 부동화 스트레스유발 생쥐에서 작두콩과 우엉 복합물의 섭취에 의한 체중변화 시험 결과이다.
도 3는 부동화 스트레스유발 생쥐에서 작두콩과 우엉 복합물 섭취에 의한 혈중 코르티솔(Cortisol)과 세로토닌(Serotonin)생산량 변화 측정 시험 결과이다.
도면상의 CG는 작두콩을 의미하는 약어이며, AL은 우엉을 의미하는 약어이다.
도면상의 IM_S는 부동화 스트레스 (immobilization stress)를 의미하는 약어이다.FIG. 1 shows the results of the blood IgA level change test by the ingestion of kojong and burdock complex in passivation stress-induced mice.
FIG. 2 shows the result of weight change test by consumption of soybean and burdock complex in immobilized stress-induced mice.
FIG. 3 shows the results of measurement of changes in blood cortisol (Cortisol) and serotonin (Serotonin) production by the ingestion of soybean curd and burdock complex in passivation stress-induced mice.
CG in the drawing is an abbreviation for soybean koji, and AL is an abbreviation for burdock.
IM_S in the drawing is an abbreviation for immobilization stress.
이하 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에 의하면 작두콩(Canavalia gladiata, 도두(刀豆)), 우엉(Arctium lappa L.), 또는 이들의 혼합물을 포함하는 스트레스 완화용 식품 조성물을 제공한다.According to the present invention, there is provided a food composition for stress relief comprising Canavalia gladiata , Tobacco, burdock ( Arctium lappa L. ), or a mixture thereof.
작두콩(Canavalia gladiata)은 장미목 콩과에 속하는 한해살이 덩굴성 식물로서, 줄기에 털이 없으며 콩 낟알 한 개의 길이가 2~3 cm, 무게가 1.5~3 g으로 콩 종류 중에서 크기가 가장 크고 맛도 뛰어난 것으로 알려져 있다. 잎은 잎자루가 길고 3개의 작은잎으로 된다. 작두콩의 꽃은 연한 홍자색 또는 흰색이고, 여름에 잎겨드랑이에서 긴 꽃줄기가 자라서 총상으로 달린다. 꼬투리 끝이 굽어 있거나 갈고리 모양을 하고 있고 길이 20 ~ 30 cm, 나비 5cm 내외이며 10개 내외의 콩이 들어 있다. 콩은 3 cm 정도이고 한쪽에 긴 좌(座)가 있다. 작두콩의 색깔은 붉은색 또는 흰색이 있으며, 모두 식용으로 사용가능하다. 종자, 껍질, 잎, 줄기, 뿌리 등 모든 부위는 식품소재로 활용될 수 있으며, 작두콩에는 가수분해 효소인 우레아제 (urease), 혈구응집소 (hemagglutinin), 카나발린 (canavalin), 리놀렌산, 사포닌, 콜린, 레시신, 식이 섬유소, 그리고 단백질 등의 다양한 생리활성물질이 함유되어 있다. Canavalia gladiata ) is a perennial vine plant belonging to the rosewood legume. It has no hairs on the stem. It has a length of 2 ~ 3 cm and a weight of 1.5 ~ 3 g. Leaves have long petiole and three small leaves. The flower of the soybean is light reddish purple or white, and a long flower stem grows from the axil of the leaf in the summer and runs with a gunshot. The end of the pod is curved or hooked, 20 ~ 30cm long, 5cm wide, and contains about 10 beans. The beans are about 3 cm long and have long seats on one side. The color of red beans is red or white, all of which can be used for food. Seeds, shells, leaves, stems and roots can be used as food materials. Soybean seeds contain the hydrolytic enzymes urease, hemagglutinin, canavalin, linolenic acid, saponin, choline, It contains various physiologically active substances such as lecithin, dietary fiber, and protein.
작두콩을 한방에서는 도두(刀豆)라고 하며, 적색종은 꼬투리를 이용하고, 백색종은 콩을 주로 이용한다.Soybean is called red bean in one room, red bean is used in pod, white bean is mainly used in white bean.
우엉(Arctium lappa L., Burdock)은 높이 1.5m이고 줄기는 자주색을 띠며 곧게 자란다. 뿌리줄기는 굵고, 곧게 뻗는다. 뿌리와 씨는 한약재로 쓰며, 뿌리줄기는 식용한다. 품종으로는 뿌리가 길고 굵은 농야천과 육질이 좋고 뿌리가 짧은 사천 등이 있다. Burdock (Arctium lappa L. , Burdock) is 1.5 m high and the stem is purple and grows straight. Roots are thick and straight. Roots and seeds are used as medicinal herbs, and rootstocks are edible. The varieties have long roots, thick agar, good quality meat, and short roots.
우엉 뿌리에는 아눌린과 약간의 팔미트산이 함유되어 있으며, arctiin, arctigenin, isoarctigenin, archidic acid, alkaloid, 지방유 등이 들어있다. 특히 isochlorogenic acid를 다량 함유하여 잘게 썰어 방치하면 산화되어 변색한다. The root of burdock contains acinic acid and some palmitic acid, and contains arctin, arctigenin, isoarctigenin, archidic acid, alkaloid, and fatty oil. Especially, isochlorogenic acid is contained in large quantity and it is oxidized and discolored when it is left to slice.
상기 작두콩, 우엉, 또는 이들의 혼합물은 추출물 형태로 포함될 수 있으며, 상기 혼합 추출물은 동결 건조된 분말 또는 농축된 진액 형태로 포함될 수 있다.The soybean curd, burdock, or a mixture thereof may be contained in the form of an extract, and the mixed extract may be contained in the form of a lyophilized powder or a concentrated liquid.
상기 작두콩, 우엉, 또는 이들의 혼합물은 직접 건조 및 미분하여 분말을 사용할 수도 있으나, 스트레스 완화 효과 및 흡수율을 높이기 위하여 추출물 형태로 포함될 수 있으며, 특히 이들 추출물을 동결 건조시키거나 농축된 형태로 포함되는 것이 바람직하다.The soybean curd, burdock, or a mixture thereof may be directly dried and pulverized and used as a powder. However, the powder may be used in the form of an extract to enhance the stress relieving effect and the absorption rate. In particular, the extract may be lyophilized or contained in a concentrated form .
본 발명의 일 실시예에 의하면 상기 혼합 추출물은 유기용매추출물, 수추출물, 초임계추출물, 중탕추출물 형태일 수 있다.According to one embodiment of the present invention, the mixed extract may be in the form of an organic solvent extract, a water extract, a supercritical extract, and a hot water extract.
상기 추출 용매의 예로는 정제수; 메탄올, 에탄올, 이소프로필알코올, 부탄올 등의 탄소수 1 내지 10의 저급 알코올; 글리세롤, 에틸렌글리콜, 프로필렌 글리콜, 1,3-부틸렌 글리콜 등의 탄소수 2 내지 30의 다가 알코올; 및 석유에테르, 메틸아세테이트, 에틸아세테이트, 벤젠, 헥산, 메틸렌클로라이드, 디에틸에테르, 디클로로메탄, 클로로포름의 등의 탄소수 1 내지 30의 탄화수소계 용매 등이 있다.Examples of the extraction solvent include purified water; Lower alcohols having 1 to 10 carbon atoms such as methanol, ethanol, isopropyl alcohol and butanol; Polyhydric alcohols having 2 to 30 carbon atoms such as glycerol, ethylene glycol, propylene glycol, and 1,3-butylene glycol; And hydrocarbon solvents having 1 to 30 carbon atoms such as petroleum ether, methyl acetate, ethyl acetate, benzene, hexane, methylene chloride, diethyl ether, dichloromethane and chloroform.
상기 추출물은 작두콩 및/또는 분쇄된 우엉에 대해 추출용매를 4~10 배 가하여 추출할 수 있다. 상기 추출 용매가 물인 경우에는 70 내지 120에서 3 시간 내지 12 시간 동안 열수 추출하고, 추출용매가 유기 용매인 경우에는 20 내지 40에서 12 시간 내지 72시간 동안 냉침 추출하는 것이 바람직하다. 또는 물과 유기 용매의 혼합 용매로 추출하는 경우에는 냉침 추출하는 것이 바람직하다.The extract may be extracted by adding 4 to 10 times the extraction solvent to soybean curd and / or ground burdock. When the extraction solvent is water, it is preferably subjected to hot water extraction at 70 to 120 hours for 3 hours to 12 hours. When the extraction solvent is an organic solvent, it is preferable to perform cold extraction at 20 to 40 hours for 12 hours to 72 hours. Or when it is extracted with a mixed solvent of water and an organic solvent, it is preferable to carry out cold extraction.
상기 추출 용매는 유효 성분을 보다 잘 추출하기 위해서는 물에 대해 에탄올이 부피%로 50~80%인 용매가 바람직하며, 이렇게 추출된 추출물을 동결 건조, 또는 감압 농축기를 이용하여 증발시켜 건조 분말로 제조할 수 있다.The extraction solvent is preferably a solvent in which ethanol is contained in an amount of 50 to 80% by volume with respect to water in order to extract the active ingredient better. The extracted extract is evaporated using a lyophilizer or a vacuum condenser to prepare a dry powder can do.
본 발명의 일 실시예에 의하면 작두콩(또는 그의 추출물)과 우엉(또는 그의 추출물)은 동일 형태(예를 들어, 원재료, 추출분말, 진액, 일정 비율의 추출액 등)를 기준으로 하여, 작두콩: 우엉의 중량비로서 1:3 ~1:5로 혼합된 것이 바람직하다. According to one embodiment of the present invention, the soybean curd (or an extract thereof) and the burdock (or an extract thereof) As a weight ratio of 1: 3 to 1: 5.
작두콩과 우엉은 단독 만으로도 스트레스 완화 효과가 나타나지만 작두콩에 우엉을 혼합하는 경우 바람직한 상승 효과가 나타나며, 특히 상기 혼합비로 포함될 때 보다 큰 스트레스 완화에 대한 상승 효과를 나타내었다.The soybean and burdock alone showed a stress relieving effect. However, when the soybean curd was mixed with the burdock, the desirable synergistic effect was exhibited.
상기 작두콩과 우엉의 혼합 추출물은 각각을 추출 후 혼합하거나, 작두콩과 우엉 원물을 혼합 후 상기 방법으로 동시에 추출하는 것도 가능하다. 작두콩과 우엉 원물을 혼합 후 추출하고자 하는 경우, 두 원물의 크기를 동일/유사하게 절단하거나 또는 분쇄 혼합하여 추출하는 것이 바람직하다.The mixed extracts of soybean and burdock can be extracted and mixed, or the soybean and burdock raw materials can be mixed and extracted simultaneously by the above method. When the soybean and burdock raw materials are to be mixed and then extracted, it is preferable that the two raw materials are cut in the same or similar size or pulverized and mixed to be extracted.
본 발명의 일 실시예에 의하면, 상기 스트레스 완화용 조성물은 담체, 희석제, 부형제 및 첨가제 중 하나 이상을 더 포함하여 정제, 환제, 산제, 과립제, 분말제, 캡슐제 및 액제 제형으로 이루어진 군에서 선택된 하나로 제형된 형태로 사용될 수도 있다. According to one embodiment of the present invention, the stress relieving composition further comprises at least one of a carrier, a diluent, an excipient and an additive, and is selected from the group consisting of tablets, pills, powders, granules, powders, capsules, It may be used in a form which is formulated as one.
상기 본 발명에 더 포함될 수 있는 첨가제로는, 천연 탄수화물, 향미제, 영양제, 비타민, 광물(전해질), 풍미제(합성 풍미제, 천연 풍미제 등), 착색제, 충진제(치즈, 초콜렛 등), 팩트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH조절제, 안정화제, 방부제, 산화 방지제, 글리세린, 알콜, 탄산화제 및 과육으로 이루어진 군으로부터 선택된 1종 이상의 성분을 사용할 수 있다.Examples of the additive that can be further included in the present invention include natural carbohydrates, flavors, nutrients, vitamins, minerals (electrolytes), flavors (synthetic flavors, natural flavors and the like), colorants, fillers (cheese, At least one component selected from the group consisting of fumaric acid and its salt, alginic acid and its salts, organic acid, protective colloid thickener, pH adjusting agent, stabilizer, preservative, antioxidant, glycerin, alcohol, .
상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상기 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다.Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tautatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharine, aspartame, etc.) can be advantageously used as the flavor.
상기 외에 본 발명에 따른 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로In addition to the above, the composition according to the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate etc.), pectic acid and its salts, Its salts, organic acids,
이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명에 따른 조성물은 천연 과일 쥬스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.PH adjusters, stabilizers, antiseptics, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the composition according to the present invention may contain flesh for the production of natural fruit juices and vegetable drinks.
이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다.These components may be used independently or in combination.
상기 담체, 부형제, 희석제 및 첨가제의 구체적인 예로는 이에 한정하는 것은 아니나, 락토즈, 덱스트로즈, 슈크로즈, 솔비톨, 만니톨, 에리스리톨, 전분, 아카시아 고무, 인산칼슘, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 미세결정성 셀룰로즈, 폴리비닐피롤리돈, 셀룰로즈, 폴리비닐피롤리돈, 메틸셀룰로즈, 물, 설탕시럽, 메틸셀룰로즈, 메틸 하이드록시 벤조에이트, 프로필하이드록시 벤조에이트, 활석, 스테아트산 마그네슘 및 미네랄 오일로 이루어진 그룹으로부터 선택된 1종 이상이 사용되는 것이 바람직하다.Specific examples of the carrier, excipient, diluent and additives include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, erythritol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium phosphate, calcium Silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water, sugar syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate And a mineral oil are preferably used.
본 발명에 따른 조성물을 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.When the composition according to the present invention is formulated, it is prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used.
본 발명의 일 실시예에 의하면, 상기 스트레스 완화용 식품 조성물은 스트레스 완화 효과를 나타내는 예방 및/또는 치료를 위한 건강기능식품 조성물로 사용될 수 있다.According to one embodiment of the present invention, the food composition for stress relief can be used as a health functional food composition for prevention and / or treatment showing a stress relieving effect.
본 발명에 따른 스트레스 완화용 식품 조성물은 상기 스트레스 완화용 식품 조성물을 포함하는 식품에 있어서, 상기 식품 전체 중량에 대하여 0.0001~90중량%, 바람직하게는 1~60중량%, 보다 더 바람직하게는 30~50중량%로 포함될 수 있다. The stress-relieving food composition according to the present invention is characterized in that the stress-relieving food composition contains 0.0001 to 90% by weight, preferably 1 to 60% by weight, more preferably 30 To 50% by weight.
본 발명의 상기 스트레스 완화용 식품 조성물을 첨가할 수 있는 식품으로는, 각종 식품류, 분말, 과립, 정제, 캡슐, 시럽제, 음료, 껌, 차, 비타민 복합제, 건강기능성 식품류 등이 있다. The foods to which the stress-relieving food composition of the present invention can be added include various foods, powders, granules, tablets, capsules, syrups, drinks, gums, tea, vitamin complexes, and health functional foods.
본 발명의 일 실시예에 의하면, 상기 스트레스 완화용 조성물은 스트레스 완화 효과를 나타내는 예방 및/또는 치료를 위한 약학 조성물로 사용될 수 있다.According to an embodiment of the present invention, the stress relieving composition can be used as a pharmaceutical composition for prevention and / or treatment showing a stress relieving effect.
상기 약학 조성물 내 유효성분으로서의 본 발명에 따른 추출물의 함량은 사용 형태 및 목적, 환자 상태, 증상의 종류 및 경중 등에 의하여 적절하게 조절할 수 있으며, 본 발명의 일 실시예에 의하면, 상기 약학 조성물은 상기 스트레스 완화용 조성물을 1~100mg/체중 kg을 1일 기준 유효량으로 포함할 수 있으나, 이에 한정되지는 않는다.The content of the extract according to the present invention as an active ingredient in the pharmaceutical composition may be appropriately adjusted depending on the mode and purpose of use, the condition of the patient, the type of symptoms and the severity of the symptoms. According to one embodiment of the present invention, The composition for stress relief may include 1 to 100 mg / kg of body weight as an effective amount per day, but is not limited thereto.
본 발명에 의한 조성물은 스트레스 완화에 관한 것으로서, 인체의 질병 원인이 되는 스트레스를 완하시키는데 기여하는 조성물을 의미한다.The composition according to the present invention relates to stress relief, and refers to a composition that contributes to relieving stress that is a cause of disease in the human body.
스트레스 완화(감소)의 기능성을 확인하기 위한 마커는 생리적 지표와 행동적 지표, 인체적용시험에서 설문조사를 통한 심리적 지표가 있다.Markers to identify the function of stress relief (reduction) are physiological indicators and behavioral indicators, and psychological indicators through surveys in human application tests.
생리적 지표에는 뇌 신경세포 생존율, 젖산탈수소효소 (LDH; Lactate dehydrogenase), 조직무게, 세로토닌과 그의 대사체 (5-HIAA), 도파민과 그의 대사체 (DOPAC, HVA), 노르에피네프린, 코르티코스테론/코르티솔, 싸이토카인 (IL-6, TNF-α 등), 부신피질자극 호르몬 (ACTH; Adrenocorticotropic hormone), 부신피질자극 호르몬 유리 호르몬 (CRH; corticotropin-releasing hormone), 신경세포 증식인자 (NGF; Nerve growth factor), 시냅토파이신 (Synaptophysin), 타액 아밀라아제, 타액 IgA, 혈압, 섬박수, 뇌파 등이 있다.Physiological indicators include brain neuron survival rate, lactate dehydrogenase (LDH), tissue weight, serotonin and its metabolites (5-HIAA), dopamine and its metabolites (DOPAC, HVA), norepinephrine, corticosterone / Corticotropin-releasing hormone (CRH), nerve growth factor (NGF), cortisol, cortisol, cytokine (IL-6 and TNF-α), adrenocorticotropic hormone (ACTH) ), Synaptophysin, saliva amylase, saliva IgA, blood pressure, island clapping, and brain waves.
행동적 지표에는 스트레스 관련 행동, 고가 십자미로 검사, 방어적 매장 시험, 자당선호도 검사, 강제 수영검사, 꼬리 현수법, NSF(novelty suppression of feeding), 거주자 침입자 시험 (Resident-intruder test) 등이 있다.Behavioral indicators include stress-related behaviors, elevated cross-lab tests, defensive store tests, sucrose preference tests, forced swimming tests, tail suspensions, novelty suppression of feeding (NSF), and resident-intruder testing .
뇌 신경세포 생존율은 신경계를 구성하는 주된 세포인 뇌 신경세포 (SK-N-BE(2)C cell, PC12 cell 등)에 시험물질을 처리하여 세포 생존율을 측정함으로서 시험물질을 평가할 수 있다.Cerebral nerve cell survival rate can be evaluated by measuring the cell survival rate by treating the test substance with the brain nerve cell (SK-N-BE (2) C cell, PC12 cell, etc.), the main cell constituting the nervous system.
젖산탈수소효소(Lactate dehydrogenase, LDH) L 젖산(L-lactic acid)을 탈수소하여 L피루빈산 (L-pyruvic acid)으로 만드는 반응을 촉매하는 효소로서 대부분의 조직에 존재한다. 조직이 손상된 경우, 세포내 효소의 이탈이 일어나 젖산탈수소효소도 유리된다. 일반적으로 젖산탈수소효소의 농도가 높으면 세포 손상되었음을 의미한다.Lactate dehydrogenase (LDH) L is an enzyme that catalyzes the reaction of L-lactic acid to L-pyruvic acid by dehydrogenation. It exists in most tissues. When the tissue is damaged, the intracellular enzyme is released and the lactate dehydrogenase is also liberated. Generally, a high concentration of lactate dehydrogenase means that the cells are damaged.
부신 및 비장의 조직무게를 측정함으로서 스트레스의 정도를 측정할 수 있다. 부신은 좌우 콩팔 위에 각 각 한 개씩 있는 3각 형의 작은 내분비선으로 부신피질에서는 분되는 코르티솔은 스트레스에 대응하여 분비되며, 부신수질에서는 나오는 카테콜라민들은 스트레스에 급히 반응하는 호르몬 등을 분비한다. 따라서, 스트레스에 의해 부신 비대와 면역과 관련된 비장에서는 스트레스에 의해 비장 위축이 나타날 수 있다.The degree of stress can be measured by measuring the adipose and spleen tissue weights. The adrenal gland is a small endocrine gland with one on each side of the left and right conus. Cortisol in the adrenal cortex is secreted in response to stress. Catecholamines in the adrenal gland secrete hormones that respond quickly to stress. Thus, in the spleen associated with adrenal hypertrophy and immunity due to stress, spleen atrophy may be caused by stress.
세로토닌(Serotonin)은 5-히드록시트립타민 (5-Hydroxytryptamine; 5HT) 구조의 생리활성아민으로서, 기분, 행동, 식욕, 수면, 근수축과 관련된 기능에 관여한다. 세로토닌이 지나치게 많으면 뇌 기능이 흥분, 자극되고, 부족하면 우울증처럼 신체적 기능을 저하시키는 물질이다. 세로토닌 대사체로는 5-HIAA(5-Hydroxy indolacetic acid)이 있다. 세로토닌의 증가할수록 평온함의 증가를 의미한다.Serotonin is a 5-hydroxytryptamine (5HT) structure of physiologically active amine that is involved in functions related to mood, behavior, appetite, sleep and muscle contraction. Excessive serotonin stimulates the brain's function, stimulating it, and, if it is deficient, depresses the body's function. The serotonin metabolite is 5-hydroxy indolacetic acid (5-HIAA). Serotonin increases with increasing serenity.
도파민(Dopamine)은 신경전달물질의 하나로 노르에피네프린과 에피네프린의 전구물질이다. 도파민은 신체 내에서 감정을 조절하고 기분 좋게 하며, 인지와 주의 집중력, 보상, 운동기능 조절 등에 관여한다, 도파민 대사체로는 DOPAC(3,4-Dihydroxy phenyl acetic acid), HVA(Homovanillic acid) 등이 있다. 도파민의 증가는 스트레스의 감소를 의미한다.Dopamine, a neurotransmitter, is a precursor of norepinephrine and epinephrine. Dopamine is involved in the regulation of emotions in the body and makes it feel good, and it is involved in cognition and concentration, compensation, and control of motor function. Dopamine (3,4-Dihydroxyphenyl acetic acid) and HVA (Homovanillic acid) have. An increase in dopamine means a decrease in stress.
노르에피네프린 (Norepinephrine)은 신경전달물질의 하나로 노르아드레날린(Noradrenaline) 이라고도 한다. 스트레스를 받았을 때 분비되는 노르에피네프린은 심장의 수축력과 심박수를 증가시키고, 전신의 혈관을 수축시켜서 혈압을 상승시킨다. 또한 기분상태에도 관여한다. 노르에피네프린 농도가 높을 수록 스트레스가 높은 것을 의미한다.Norepinephrine, also known as Noradrenaline, is a neurotransmitter. When stressed, norepinephrine increases the contractility and heart rate of the heart, contracts the blood vessels of the whole body, and increases blood pressure. It is also involved in mood. The higher the concentration of norepinephrine, the higher the stress.
코르티코스테론(Corticosterone)또는 코르티솔(Cortisol)은 부신피질에서 분비되는 스테로이드호르몬으로 쥐의 경우 코르티코스테론, 사람의 경우 코르티솔의 형태로 분비되며 시상하부-뇌하수체-부신 축의 최종 작용물질로서 스트레스원에 대한 개체의 반응과 항상성의 조절에 관여한다. 코르티코스테론 및 코르티솔은 정신적인 스트레스를 받았을 때 상대적으로 농도가 증가하며 혈압 및 맥박을 증가시킨다. 코르티코스테론 및 코르티솔 농도가 높을수록 스트레스가 높음을 의미한다.Corticosterone or cortisol is a steroid hormone secreted from the adrenal cortex that is secreted in the form of corticosterone in rats and cortisol in humans and is the final agonist of the hypothalamus-pituitary-adrenal axis, It is involved in the regulation of the response and homeostasis of an individual. Corticosterone and cortisol increase micturition stress and increase blood pressure and pulse rate. The higher the concentration of corticosterone and cortisol, the higher the stress.
싸이토카인 (Cytokine)은 세포 사이의 신호전달을 매개하는 단백질로 인터루킨(Interluekin; IL), 인터페론(Interferon; IFN), 종양괴사인자(Tumor necrosis factors; TNF) 등이 있다. 면역세포뿐만 아니라 신경세포도 싸이토카인을 분비하여 뇌신경 기능조절에 관여한다. 염증성 싸이토카인인 IL-1β, IL-2, IL-6 TNF-α 등은 스트레스 반응 때 중추신경계에서 분비된다. 염증성 싸이토카인인 IL-1β, IL-2, IL-6, TNF-αβγ 등의 생성(발현) 양이 많을수록 스트레스 정도가 심함을 의미한다Cytokine is a protein that mediates intercellular signaling, including interleukin (IL), interferon (IFN), and tumor necrosis factors (TNF). Not only immune cells but also neurons secrete cytokines and are involved in the regulation of cranial nerve function. The inflammatory cytokines IL-1β, IL-2, and IL-6, TNF-α, are secreted by the central nervous system during the stress response. The greater the amount of IL-1β, IL-2, IL-6, and TNF-αβγ, which are inflammatory cytokines, the greater the degree of stress
부신피질자극 호르몬(ACTH; Adrenocorticotropic hormone)은 뇌하수체에서 분비되는 물질로 부신피질을 자극하여 코르티솔과 같은 스테로이드 호르몬을 분비시킨다. 인체가 스트레스를 받으면 중추신경계를 통해 이 호르몬의 분비가 촉진된다.Adrenocorticotropic hormone (ACTH) secreted from the pituitary gland stimulates the adrenal cortex to release steroid hormones such as cortisol. When the human body is stressed, the secretion of this hormone is promoted through the central nervous system.
부신피질자극 호르몬 유리 호르몬(CRH; corticotropin-releasing hormone)은 시상하부-뇌하수체 신경분비계에 의해 뇌하수체 문맥계에 분비되고, 부신피질자극 호르몬의 분비에 관여한다. 혈중의 부신피질호르몬 농도에 의해 분비가 조절된다.Corticotropin-releasing hormone (CRH) is secreted into the pituitary portal system by the hypothalamic-pituitary nervous system and is involved in the secretion of adrenocortical stimulating hormone. The secretion is regulated by the concentration of adrenocortical hormone in the blood.
신경세포 증식인자(NGF; Nerve growth factor)는 Neuro-trophic 단백질로 감각신경과 교감신경의 신경세포 발달 및 유지에 있어서 핵심적인 역할을 한다. 또한 조직과 신경 섬유말단으로부터 신경세포내로 수송되어 감각신경, 말초 아드레날린성 신경 및 중추의 콜린성 신경섬유에 대한 발달과정에 기여한다.Nerve growth factor (NGF) is a neuro-trophic protein that plays a key role in neural development and maintenance of the sensory and sympathetic nerves. It is also transported into nerve cells from tissue and nerve fiber ends and contributes to the development of sensory neurons, peripheral adrenergic neurons and cholinergic nerve fibers of the central nervous system.
시냅토파이신 (Synaptophysin)은 신경세포나 신경내분비세포의 소포막에 존재하는 당단백으로서, 발달 과정 동안 신경연접의 형성 정도와 비례하여 증가하고, 신경연접의 분포와도 일치하므로 신경 발달의 연구에 있어 많이 사용되고 있는 단백질이다.Synaptophysin is a glycoprotein present in the vesicle of neurons or neuroendocrine cells, which increases in proportion to the degree of neuronal synaptogenesis during development and is consistent with the distribution of neuronal synapses. It is a widely used protein.
타액 아밀라아제 (Salivary amylase)는 녹말의 α-1,4-글라이코사이드 결합(Glycosidic bond)을 가수분해하는 효소로서, 귀밑샘과 턱밑샘의 샘꽈리 세포에서 생성된다. 타액 아밀라아제는 교감신경의 자극에 의해 분비되며, 스트레스 상황에서 타액 아밀라아제 분비가 증가한다.Salivary amylase is an enzyme that hydrolyzes the α-1,4-glycosidic bond of starch and is produced in the glandular cells of the parotid gland and submandibular gland. Salivary amylase is secreted by sympathetic stimulation and increases secretion of saliva amylase under stress conditions.
면역글로불린A(IgA)는 혈청, 타액, 초유, 눈물, 담즙, 뇨, 분변 등의 점막 분비물 중에 많이 함유되어 있으며, 각종 병원체에 대한 방어역할을 한다. 스트레스 상황에서 증가된 코르티솔은 타액 IgA의 분비를 억제한다.Immunoglobulin A (IgA) is contained in mucous secretions such as serum, saliva, colostrum, tears, bile, urine, and feces and plays a defense role against various pathogens. Increased cortisol in stress conditions inhibits the secretion of salivary IgA.
혈압은 혈액이 혈관 벽에 미치는 압력으로서 심실이 수축할 때의 혈압인 수축기 혈압, 이완할 때의 혈압인 이완기혈압이 있다. 정상 혈압은 수축기 혈압 120-130mmHg, 이완기 혈압 80-85mmHg 내외이다. 이보다 일정 수준 이상 높아지면 고혈압, 낮아지면 저혈압이라고 한다. 스트레스는 교감신경을 자극하여 혈압상승을 유발한다.The blood pressure is the pressure on the wall of the blood vessel, that is, the systolic blood pressure, which is the blood pressure when the ventricle contracts, and the diastolic blood pressure, which is the blood pressure when relaxing. Normal blood pressure is about 120-130 mmHg in systolic blood pressure, and 80-85 mmHg in diastolic blood pressure. Higher than a certain level of high blood pressure, low blood pressure is said. Stress stimulates the sympathetic nerves and causes an increase in blood pressure.
심박수는 심장이 1분 동안 뛰는 횟수를 말하는 것으로 정상인은 안정시 약 70회/분이지만 개인마다 차이가 커서 50-100회 정도를 정상 범위로 보고 있다. 심박수 변화요인에는 체온, 운동, 수면, 섭식상태, 감정 등이 있다. 스트레스는 교감신경을 자극하여 심박수가 증가될 수 있다.The heart rate refers to the number of times the heart plays for one minute, and the normal person is about 70 times / minute when stable, but the difference is large among individuals, so the normal range is about 50-100 times. Heart rate variability factors include body temperature, exercise, sleep, feeding, and emotions. Stress may stimulate sympathetic nerves and increase heart rate.
뇌파는 뇌의 활동에 따라 일어나는 전류를 기록한 것으로 뇌파는 α, β, γ, δ, θ가 있다. 뇌파 α파의 파워 가 증가할수록, β파의 파워가 감소 할수록 스트레스가 완화됨을 의미한다.EEG records the currents that occur according to the activity of the brain. EEG has α, β, γ, δ, θ. As the power of the EEG wave increases, the stress decreases as the power of the EEG decreases.
이하, 실시예와 비교예를 통하여 본 발명을 더욱 상세히 설명한다. 다만, 본 명세서에 기재된 도면 및 실시예에 도시된 구성은 본 발명의 가장 바람직한 일 실시예에 불과할 뿐이고 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형예들이 있을 수 있음을 이해하여야 한다.Hereinafter, the present invention will be described in more detail with reference to examples and comparative examples. It should be understood, however, that the present invention is not limited to the above-described embodiments, and that various changes and modifications may be made without departing from the spirit and scope of the invention as defined in the appended claims. It is to be understood that equivalents and modifications are possible.
실시예Example : 작두콩 및 우엉 추출물의 제조: Preparation of Soybean and Burdock Extracts
작두콩 및 우엉을 각각 대한약전에 수재된 기준에 따라 에탄올과 정제수를 혼합하여 70% 주정 용매를 각각 약 4 ~ 10 배량 가하여 5 일간 실온(20±5)에서 냉침하였다. 각각 추출된 원액을 와트만 #3 여과지를 사용하여 여과하고, 여과된 추출물을 감압농축기를 이용하여 45 에서 추출 용매를 완전히 증발시켜 건조된 추출물을 각각 얻었다.Soybean koji and burdock were mixed with ethanol and purified water according to the criteria of each pharmacopoeia, and 70% alcohol was added to the mixture at about 4 to 10 times, followed by cooling at room temperature (20 ± 5) for 5 days. The extracted extracts were filtered using Wattman # 3 filter paper, and the extracted extracts were completely evaporated at 45 using a vacuum concentrator to obtain dried extracts.
실험예Experimental Example 1: One: 부동화dissimilation 스트레스유발 생쥐에서 작두콩과 우엉 복합물 섭취에 의한 혈중 In the stress-induced mice, IgAIgA 수준 변화 시험 Level change test
좁은 틀에 매일 2시간씩 21일간 움직이지 못 하게 하여 스트레스를 유발시킨 마우스에 작두콩 70%주정 추출물 (CG70%E), 우엉 70% 주정 추출물(AL70%E), 작두콩 70% 주정 추출물과 우엉 70% 주정 추출물의 1:4의 비율로 혼합한 복합물(CG+AL, 1:4)을 부동화 스트레스유발 8주령 C57BL/6에 매일 경구 투여하였다. 혈청중 IgA 수준을 측정한 결과로, 작두콩 70%주정 추출물 (CG70%E) 100 mg/kg (p<0.05) 그리고 작두콩 70% 주정 추출물과 우엉 70% 주정 추출물의 1:4의 비율로 혼합한 복합물(CG+AL, 1:4) 100 mg/kg (p<0.01), 50 mg/kg (p<0.05) 투여군이 부동화대조군 (IM_S-CTL)에 비하여 통계학적으로 유의성 있게 IgA 수준이 증가를 나타났다.70% koji extract (CG70% E), 70% burdock extract (AL70% E), 70% koji bean extract and burdock 70 were used in the stressed mice for 2 hours each day for 2 hours in a narrow frame (CG + AL, 1: 4) mixed at a ratio of 1: 4 of the extracts of 1% to 4% of the extract was orally administered to C57BL / 6 at 8 weeks of passivation stress induction. As a result of measuring IgA levels in serum, 70% koji extract (CG70% E) 100 mg / kg (p <0.05) and 70% koji extract were mixed with 1: 4 ratio of 70% IgA levels were significantly increased in the 100 mg / kg (p <0.01) and 50 mg / kg (p <0.05) groups compared with the passive control group (IM_S-CTL) appear.
특히, 작두콩 70% 주정 추출물과 우엉 70% 주정 추출물의 1:4의 비율로 혼합한 복합물에서 가장 높은 IgA 수준의 증가를 나타내었다.In particular, the highest IgA level was observed in the combination of 70% kojong extract and 70% burdock extract in a ratio of 1: 4.
이의 결과를 도 1에 나타내었다.The results are shown in Fig.
실험예Experimental Example 2: 2: 부동화dissimilation 스트레스유발 생쥐에서 작두콩과 우엉 복합물의 섭취에 의한 체중변화 시험 Weight change test by ingestion of soybean and burdock complex in stress-induced mice
작두콩 70%주정 추출물 (CG70%E), 우엉 70% 주정 추출물(AL70%E), 작두콩 70% 주정 추출물과 우엉 70% 주정 추출물의 1:4의 비율로 혼합한 복합물(CG+AL, 1:4)을 부동화 스트레스를 매일 2시간씩 21일간 부동화로 스트레스유발 8주령 C57BL/6에 매일 경구투여하였다. 체중변화를 측정한 결과 부동화대조군 (IM_S-CTL)은 정상군에비하여 체중 감소가 나타났고, 작두콩 70%주정 추출물 (CG70%E) 100 mg/kg, 우엉 70% 주정 추출물(AL70%E) 100 mg/kg, 그리고 작두콩 70% 주정 추출물과 우엉 70% 주정 추출물의 1:4의 비율로 혼합한 복합물(CG+AL, 1:4) 100mg/kg 투여군이 부동화대조군 (IM_S-CTL)에 비하여 체중감소가 적게 나타났다.(CG + AL, 1: 4) mixture of 70% koji extract (CG70% E), 70% burdock extract (AL70% E), 70% koji extract and 70% 4) was orally administered to stress-induced 8 week old C57BL / 6 by immobilization for 21 days for 2 hours each day. (70%) of alcohol extract (CG70% E) 100 mg / kg, 70% of burdock extract (AL70% E) and 100% of body weight of immature control group (IM_S-CTL) (CG + AL, 1: 4) 100 mg / kg of the mixture of 1: 4 ratio of the extract of cormorant and 70% of the koji extract to the weight of the control group (IM_S-CTL) Decrease.
특히, 작두콩 70% 주정 추출물과 우엉 70% 주정 추출물의 1:4의 비율로 혼합한 복합물에서 가장 낮은 체중감소를 나타내었다.In particular, the lowest weight loss was observed in the combination of 70% koji extract with 70% koji extract and 1: 4 ratio.
이의 결과를 도 2에 나타내었다.The results are shown in Fig.
실험예Experimental Example 3: 3: 부동화dissimilation 스트레스유발 생쥐에서 작두콩과 우엉 복합물 섭취에 의한 혈중 In the stress-induced mice, 코티졸(Cortisol)과Cortisol and 세로토닌( Serotonin ( SerotoninSerotonin )생산량 변화 측정 시험) Production change measurement test
작두콩 70%주정 추출물 (CG70%E), 우엉 70% 주정 추출물(AL70%E), 작두콩 70% 주정 추출물과 우엉 70% 주정 추출물의 1:4의 비율로 혼합한 복합물(CG+AL, 1:4)을 부동화 스트레스를 매일 2시간씩 21일간 부동화로 스트레스유발 8주령 C57BL/6에 매일 경구 투여하였다. 혈청중 행복의 감정을 느끼게 해주는 호르몬인 세로토닌(Serotonin) 수준을 측정한 결과 작두콩 70%주정 추출물 (CG70%E) 100 mg/kg (p<0.05) 그리고 작두콩 70% 주정 추출물과 우엉 70% 주정 추출물의 1:4의 비율로 혼합한 복합물(CG+AL, 1:4) 100 mg/kg (p<0.01), 50 mg/kg (p<0.05) 투여군이 부동화대조군 (IM_S-CTL)에 비하여 통계학적으로 유의성 있게 세로토닌(Serotonin) 수준이 증가를 나타났다. 혈청중 스트레스 호르몬인 코르티솔(Cortisol) 수준을 측정한 결과 작두콩 70%주정 추출물 (CG70%E) 100 mg/kg (p<0.05) 그리고 작두콩 70% 주정 추출물과 우엉 70% 주정 추출물의 1:4의 비율로 혼합한 복합물(CG+AL, 1:4) 100 mg/kg (p<0.01), 50 mg/kg (p<0.05) 투여군이 부동화대조군 (IM_S-CTL)에 비하여 통계학적으로 유의성 있게 코르티솔(Cortisol) 수준이 감소를 나타났다.(CG + AL, 1: 4) mixture of 70% koji extract (CG70% E), 70% burdock extract (AL70% E), 70% koji extract and 70% 4) was orally administered to stress-induced 8 week old C57BL / 6 by immobilization for 21 days for 2 hours each day. Serotonin, a hormone that makes the sensation of happiness in the serum, was measured. The results showed that 70% kojong extract (CG70% E) 100 mg / kg (p <0.05) and 70% kojong extract and 70% (CG + AL, 1: 4) 100 mg / kg (p <0.01) and 50 mg / kg (p <0.05) Serotonin levels were found to be significantly increased. Cortisol levels in the serum were 70%, 70%, 70%, 70% and 70%, respectively, of the extracts of corn (70% (P <0.01) and 50 mg / kg (p <0.05) were significantly higher than the passive control group (IM_S-CTL) (Cortisol) levels were decreased.
특히, 작두콩 70% 주정 추출물과 우엉 70% 주정 추출물의 1:4의 비율로 혼합한 복합물에서 가장 높은 세로토닌 수준의 증가와 가장 높은 코르티솔 수준의 감소를 나타내었다.In particular, the highest serotonin levels and the highest levels of cortisol levels were observed in the combination of 70% kojong extract and 70% burdock extract at a ratio of 1: 4.
이의 결과를 도 3에 나타내었다.The results are shown in Fig.
본 발명에 따른 스트레스 완화용 식품 조성물을 포함하는 건강기능식품 및 약학 조성물의 제제예를 설명하나, 본 발명은 이에 한정되는 것은 아니다.Examples of the formulations of health functional foods and pharmaceutical compositions containing the food composition for stress relief according to the present invention will be described, but the present invention is not limited thereto.
[제조예 1: 스트레스 완화용 식품 조성물][Production Example 1: Food Composition for Stress Relief]
실시예 1에 따라 작두콩 및 우엉의 70% 주정 추출물을 각각 제조한 후 건조 및 분쇄하여 분말을 제조하였다. 제조된 분말을 작두콩과 우엉을 1:4의 중량비로 혼합하여 스트레스 완화용 식품 조성물을 제조하였다.According to Example 1, 70% of the extracts of soybean curd and burdock were respectively prepared, dried and pulverized to prepare powders. The prepared powder was mixed with soybean curd and burdock at a weight ratio of 1: 4 to prepare a food composition for stress relief.
[스트레스 완화용 식품] [Food for stress relief]
(1) (One) 선식Wire 제조 Produce
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60메쉬의 분말로 준비하였다. 검정콩, 검정깨 및 들깨 각각을 공지의 방법으로 쪄서 건조시킨 후 배전 및 분쇄하여 입도 60메쉬의 분말로 준비하였다. 이후, 현미 30중량%, 율무 15중량%, 보리 20중량%, 찹쌀 9중량%, 들깨 7중량%, 검정콩 8중량%, 검정깨 7중량%, 제조예 1에서 제조한 스트레스 완화용 식품 조성물 3중량%, 영지 0.5중량% 및 지황 0.5중량%를 혼합하여 선식을 제조하였다.Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and then the mixture was prepared into powder having a particle size of 60 mesh by a pulverizer. Black beans, black sesame seeds and perilla seeds were each steamed and dried by known methods, and then power distribution and pulverization were carried out to prepare powder having a particle size of 60 mesh. Thereafter, 30% by weight of brown rice, 15% by weight of yulmu, 20% by weight of barley, 9% by weight of glutinous rice, 7% by weight of perilla seed, 8% by weight of black soybean, 7% by weight of black sesame seed, By weight, 0.5% by weight of Ganoderma lucidum, and 0.5% by weight of Sorbitol were mixed to prepare an electric wire.
(2) (2) 츄잉껌Chewing gum 제조 Produce
껌 베이스 20중량%, 설탕 76.9중량%, 향료 1중량%, 물 2중량% 및 제조예 1에서 제조한 스트레스 완화용 식품 조성물 0.1중량%를 배합하여 통상의 방법으로 츄잉껌을 제조하였다.Chewing gum was prepared in a conventional manner by mixing 20% by weight of a gum base, 76.9% by weight of sugar, 1% by weight of a flavor, 2% by weight of water and 0.1% by weight of a food composition for stress relief prepared in Preparation Example 1.
(3) 건강음료 제조(3) Health drinks manufacturing
꿀 0.26중량%, 치옥토산아미드 0.0002중량%, 니코틴산아미드 0.0004중량%, 염산리보플라빈나트륨 0.0001중량%, 염산피리독신 0.0001중량%, 이노시톨 0.001중량%, 오르트산 0.002중량%, 물 98.7362중량% 및 제조예 1에서 제조한 스트레스 완화용 식품 조성물 1중량%를 배합하여 통상의 방법으로 건강 음료를 제조하였다.0.0001 wt.% Of niacinamide, 0.0001 wt.% Of sodium riboflavin, 0.0001 wt.% Of pyridoxine hydrochloride, 0.001 wt.% Of inositol, 0.002 wt.% Of orthoacetic acid, 98.7362 wt.% Of water and 0.2 wt. 1% by weight of a food composition for stress relief prepared in Preparation Example 1 was blended to prepare a health drink by a conventional method.
(4) 건강보조식품 제조(4) health supplement manufacturing
스피루리나 55중량%, 구아검효소 분해물 10중량%, 비타민 B1 염산염 0.01중량%, 비타민 B6 염산염 0.01중량%, DL-메티오닌 0.23중량%, 스테아린산 마그네슘 0.7중량%, 유당 22.2중량% 및 옥수수전분 1.85중량%와 제조예 1에서 제조한 스트레스 완화용 식품 조성물 10중량%를 배합하여 통상의 방법으로 정제형 건강보조식품을 제조하였다.A mixture of 55% by weight of spirulina, 10% by weight of guar gum enzyme hydrolyzate, 0.01% by weight of vitamin B1 hydrochloride, 0.01% by weight of vitamin B6 hydrochloride, 0.23% by weight of DL-methionine, 0.7% by weight of magnesium stearate, And 10% by weight of the food composition for stress relief prepared in Preparation Example 1 were mixed to prepare a refillable health supplement food by a conventional method.
(5) 주류 제조(5) Manufacture of alcoholic beverages
제조예 1에서 제조한 스트레스 완화용 식품 조성물 0.5중량%를 소주, 맥주, 양주 또는 과실주와 혼합하여 에멀전 상태로 만든 후, 고속믹서기로 9,000 rpm에서 혼합하여 작두콩, 우엉 또는 작두콩과 우엉 혼합물이 함유된 주류를 제조하였다.0.5% by weight of the food composition for stress relief prepared in Preparation Example 1 was mixed with soju, beer, liquor or fruit wine into an emulsion state and then mixed at 9,000 rpm with a high-speed mixer to prepare a mixture containing soybean curd, burdock, Liquor was produced.
[스트레스 완화용 건강기능식품 또는 약학 조성물][Health functional food or pharmaceutical composition for relieving stress]
(1) (One) 산제Powder 제조 Produce
제조예 1에서 제조한 스트레스 완화용 식품 조성물 2 g에 유당 1 g을 혼합하고, 기밀포에 충진하여 산제를 제조하였다.2 g of the food composition for stress relief prepared in Preparation Example 1 was mixed with 1 g of lactose and filled in an airtight container to prepare a powder.
(2) 정제 제조(2) Preparation of tablets
제조예 1에서 제조한 스트레스 완화용 식품 조성물 100 ㎎, 옥수수전분 100 ㎎, 유당 100 ㎎ 및 스테아린산 마그네슘 2 ㎎을 혼합한 후 통상의 정제 제조방법에 따라 타정하여 정제를 제조하였다.100 mg of corn starch, 100 mg of lactose, and 2 mg of magnesium stearate prepared in Preparation Example 1 were mixed, and tablets were prepared by tableting according to a conventional tablet preparation method.
(3) (3) 캡슐제Capsule 제조 Produce
제조예 1에서 제조한 스트레스 완화용 식품 조성물 100 ㎎, 옥수수전분 100 ㎎, 유당 100 ㎎ 및 스테아린산 마그네슘 2 ㎎을 혼합한 후 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.100 mg of the food composition for stress relief prepared in Preparation Example 1, 100 mg of corn starch, 100 mg of lactose and 2 mg of magnesium stearate were mixed and filled in gelatin capsules to prepare capsules.
도면상의 CG는 작두콩을 의미하는 약어이며, AL은 우엉을 의미하는 약어이다.
도면상의 IM_S는 부동화 스트레스 (immobilization stress)를 의미하는 약어이다.CG in the drawing is an abbreviation for soybean koji, and AL is an abbreviation for burdock.
IM_S in the drawing is an abbreviation for immobilization stress.
Claims (11)
상기 작두콩과 우엉이 중량비로서 1:4의 비율로 혼합된 혼합물로 포함된 것을 특징으로 하는 스트레스 완화용 식품 조성물.It contains Canavalia gladiata (豆豆) and burdock ( Arctium lappa L. )
Wherein the soybean curd and the burdock are mixed in a weight ratio of 1: 4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160105624A KR101880245B1 (en) | 2016-08-19 | 2016-08-19 | Food Composition for Anti-stress effect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160105624A KR101880245B1 (en) | 2016-08-19 | 2016-08-19 | Food Composition for Anti-stress effect |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180020762A KR20180020762A (en) | 2018-02-28 |
KR101880245B1 true KR101880245B1 (en) | 2018-07-20 |
Family
ID=61401515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160105624A KR101880245B1 (en) | 2016-08-19 | 2016-08-19 | Food Composition for Anti-stress effect |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101880245B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200040567A (en) | 2018-10-10 | 2020-04-20 | 건국대학교 글로컬산학협력단 | A composition having effects of recovering stress comprising methylsulphonylmethane |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102318883B1 (en) * | 2020-12-14 | 2021-10-29 | 주식회사 천연스토리 | Method for manufacturing companion animal feed containing burdock extract |
-
2016
- 2016-08-19 KR KR1020160105624A patent/KR101880245B1/en active IP Right Grant
Non-Patent Citations (6)
Title |
---|
우엉차가 스트레스를 날려버린다구요? - 자연주의병원/자연병원/자연주의출산/스트레스에 좋은음식/건강음식/좋은차/차효능 (네이버 블로그, http://blog.naver.com/hatvit12/220240716941) (2015.01.15.) * |
우엉차가 스트레스를 날려버린다구요? - 자연주의병원/자연병원/자연주의출산/스트레스에 좋은음식/건강음식/좋은차/차효능 (네이버 블로그, http://blog.naver.com/hatvit12/220240716941) (2015.01.15.)* |
우엉차가 스트레스를 날려버린다구요? - 자연주의병원/자연병원/자연주의출산/스트레스에 좋은음식/건강음식/좋은차/차효능 (네이버 블로그, http://blog.naver.com/hatvit12/220240716941) (2015.01.15.), 사본 1부. * |
작두콩차(자연하루)_ 밭에서 나는 소고기인 구수한 건강차로 면역력 UP!!! (네이버 블로그, http://bjj3280.blog.me/220728865910) (2016.06.06.) * |
작두콩차(자연하루)_ 밭에서 나는 소고기인 구수한 건강차로 면역력 UP!!! (네이버 블로그, http://bjj3280.blog.me/220728865910) (2016.06.06.)* |
작두콩차(자연하루)_ 밭에서 나는 소고기인 구수한 건강차로 면역력 UP!!! (네이버 블로그, http://bjj3280.blog.me/220728865910) (2016.06.06.), 사본 1부. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200040567A (en) | 2018-10-10 | 2020-04-20 | 건국대학교 글로컬산학협력단 | A composition having effects of recovering stress comprising methylsulphonylmethane |
Also Published As
Publication number | Publication date |
---|---|
KR20180020762A (en) | 2018-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103619346B (en) | For preventing or treat the compositions comprising herbal combination extract of diabetic peripheral neuropathy | |
KR100795822B1 (en) | Natural plant extract composition for prevention and recovery of hyperlipidemia and stroke, natural tee including the same as effective components and the preparation method thereof | |
KR102113583B1 (en) | Composition lemon and orange extracts for improving sleep disturbance caused by caffeine | |
KR101817055B1 (en) | Food composition having anti-obesity, anti-cancer, anti-oxidative and immunity enhancing activities | |
CN110519997A (en) | Pass through the antibiosis of moringa oleifera leaf extractive and the compound of eucommia ulmoides extracts, anti-oxidant, anti-inflammatory, inhibition periodontal bone lesion and the method for regenerating periodontal bone alleviation gingivitis and periodontitis | |
KR101947786B1 (en) | Food Composition for Stress Relaxation, Fatigue Recovery or Athletic Performance Enhancement Comprising Extract of herb | |
KR20160144791A (en) | Composition for relieving menopausal symptom | |
KR101751211B1 (en) | Composition for improving sexual function, Functional food Composition for improving sexual function comprising of the same and Manufacturing method thereof | |
KR101880245B1 (en) | Food Composition for Anti-stress effect | |
KR101788253B1 (en) | Composition for improving male sexual function comprising the extract of Alpinia Officinarum, Smilacina Japonica & Black Garlic | |
KR102092509B1 (en) | Food composition for preventing and improving of dementia | |
KR101673204B1 (en) | Health beverage using natural materials with protection of brain cells | |
KR101902510B1 (en) | Composition for anti-stress effect, Functional Food and Pharmaceutical composition including the same | |
KR101322450B1 (en) | A breeding method of protaetia breviitarsis, protaetia breviitarsis using the same | |
US8524287B2 (en) | Composition for the prevention and treatment of postmenopausal syndrome containing extracts or fractions of Aceriphyllum rossii as an effective ingredient | |
KR100850503B1 (en) | Composition for improving erectile dysfunction and erection maintenance containing the extract of crude drug complex | |
KR102242400B1 (en) | Functional Food for preventing Composition for preventing inflammatory disease due to stress | |
KR102050554B1 (en) | Composition for hangover treatment and manufacturing method for the same | |
KR101862836B1 (en) | Pharmaceutical composition comprising heracleum moellendorffii hance extract for preventing or treating depression | |
KR101895024B1 (en) | Composition for Enhancement of Immunity | |
KR20200081550A (en) | Composition containing an fermented extract of protaetia brevitarsis seulensis as an active ingredient and manufacturing the same | |
KR102330844B1 (en) | Composition For Improving Sexual Function Containing 17 Herbal Ingredients And Schisandra Chinensis, Rubus Coreanus, Lycium Chinense, Torilis Japonica, And Cuscuta Australis | |
KR20190103665A (en) | Food composition for improving or preventing obesity containing extract of saururus chinensis | |
KR102275824B1 (en) | The anti-diabetes composition containing extract mixture and manufaturing method thereof | |
KR102494072B1 (en) | Composition for improving or preventing depression comprising herbal extracts and method for preparing thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) |